SCHEMBL24674301

SCHEMBL24674301

Cc1ccc(CNc2ncnc3ncc(-c4ccc(F)cc4)nc23)nn1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 5/20 0.38
NOS1 P29475 1/20 0.36
WNT3A P56704 2/20 0.35
HDAC1 Q13547 1/20 0.34
HDAC8 Q9BY41 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
AURKA O14965 1/20 0.34
ABL1 P00519 1/20 0.34
NTRK1 P04629 1/20 0.34
LCK P06239 1/20 0.34
CSF1R P07333 1/20 0.34
RET P07949 1/20 0.34
PDGFRB P09619 1/20 0.34
PIM1 P11309 1/20 0.34
PDGFRA P16234 1/20 0.34
FLT3 P36888 1/20 0.34
MAPK8 P45983 1/20 0.34
CDK8 P49336 1/20 0.34
MAP2K1 Q02750 1/20 0.34
MAP4K2 Q12851 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29427588 1.00 MET (0.38) METNOS1WNT3AHDAC1HDAC8
SCHEMBL29427592 0.84 MET (0.46) METNOS1WNT3AHDAC1HDAC6
SCHEMBL24674190 0.84 MAP4K4 (0.51) NTRK1PIM1MAP4K4LMNA
SCHEMBL24674165 0.84 MET (0.46) METNOS1WNT3AHDAC1HDAC6
SCHEMBL29427602 0.80 LMNA (0.42) LMNAKDM4ETP53MAPK1
SCHEMBL24674191 0.80 LMNA (0.42) LMNAKDM4ETP53MAPK1
SCHEMBL29427593 0.77 USP10 (0.46) LMNAKDM4EMAPK1
SCHEMBL24674289 0.77 USP10 (0.46) LMNAKDM4EMAPK1
SCHEMBL29481169 0.73 CLK4 (0.55) LMNAKDM4EHPGDMAPK1
SCHEMBL28726479 0.73 CLK4 (0.55) LMNAKDM4EHPGDMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114222741-A As P2X3Suppression ofPyridopyrimidine derivatives as agents 奇斯药制品公司 2022-03-22 CN claimed
US-20230212169-A9 PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2023-07-06 US disclosed
US-20230212169-A9 PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2023-07-06 US disclosed
US-20220235060-A1 PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS CHIESI FARM SPA (IT) 2022-07-28 US disclosed
CN-114222741-A As P2X3Suppression ofPyridopyrimidine derivatives as agents 奇斯药制品公司 2022-03-22 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220235060-A1 PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS P2RX3, P2RX5, P2RX1 MET 4032/4885NOS1 2479/4885WNT3A 1251/4885
US-20230212169-A9 PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS P2RX3, P2RX5, P2RX1 MET 4032/4885NOS1 2479/4885WNT3A 1251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.